Genetic Modification of Neurons to Express Bevacizumab for Local Anti-angiogenesis Treatment of Glioblastoma

The median survival of glioblastoma multiforme (GBM) approximately 1 yr. Following surgical removal, systemic therapies are limited by the blood-brain barrier. To circumvent this, we developed a method to modify neurons with the genetic sequence for therapeutic monoclonal antibodies using adeno-asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Hicks, Martin J., Funato, Kosuke, Wang, Lan, Aronowitz, Eric, Dyke, Jonathan P., Ballon, Douglas J., Havlicek, David F., Frenk, Esther Z., De, Bishnu P., Chiuchiolo, Maria J., Sondhi, Dolan, Hackett, Neil R., Kaminsky, Stephen M., Tabar, Viviane, Crystal, Ronald G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293257/
https://www.ncbi.nlm.nih.gov/pubmed/25501993
http://dx.doi.org/10.1038/cgt.2014.58

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293257/
https://www.ncbi.nlm.nih.gov/pubmed/25501993
http://dx.doi.org/10.1038/cgt.2014.58

Ejemplares similares